Risk of endophthalmitis following anti-VEGF injection is low
The incidence of suspected endophthalmitis in patients who have received intravitreal anti-vascular endothelial growth factor (VEGF) treatments in a community setting is very low, according to a study published in the May 2008 issue of the American Journal of Ophthalmology.
The incidence of suspected endophthalmitis in patients who have received intravitreal anti-vascular endothelial growth factor (VEGF) treatments in a community setting is very low, according to a study published in the May 2008 issue of the American Journal of Ophthalmology.
Suman Pilli of the Vitreous Retina Macula Consultants of New York and the LuEsther T. Mertz Retinal Research Center at Manhattan Eye, Ear, and Throat Hospital, New York, US and colleagues conducted a retrospective interventional case series of 10254 intravitreal anti-VEGF injections (ranibizumab, n=6347; bevacizumab, n=3501; pegaptanib, n=406) performed in an office setting without preinjection antibiotics between January 5 2005 and October 18 2007.
There were no cases of confirmed endophthalmitis and three cases of suspected endophthalmitis (ranibizumab, n=2; bevacizumab, n=1; pegaptanib, n=0), after which all three patients regained pre-injection visual acuity.
The rate of suspected endophthalmitis was 0.029%, which is comparable to the rate reported when more rigorous preventative measures are taken, such as in a clinical trials setting.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
